Biotest AG: Biotest Supervisory Board appoints new Management Board member
News: Biotest AG / Key word(s): Personnel
Biotest Supervisory Board appoints new Management Board member
As a Management Board Member, Mr Janssen will initially familiarise himself with the area of responsibility of Dr Georg Floß and will formally succeed him as Chief Operating Officer at the end of the year after Georg Floß leaves the company as planned when his contract expires.
As 'Chief Operations Officer', Mr Janssen will be responsible within the Biotest Group for Quality Operations, Commercial Operations, Production, Supply Chain Planning, Engineering and Development Plasma Proteins.
Mr Janssen served as Executive Vice President for Prothya Biosolutions, following a successful business transformation as CEO of the company in Belgium since 2017. Prior to joining Prothya, Mr Janssen spent 14 years with Pfizer and five years with its animal health spin-off Zoetis, where he held various transformative, strategic and operational roles of increasing responsibility. As part of his academic training, he holds a Master of Science in Electromechanical Engineering, a Master in Applied Economics and several business degrees.
"We are happy that Dr Floß and Mr Janssen will jointly shape the transition of responsibility and the strategically so important areas to ensure the continued success of the company. Mr Janssen has been very successful in the development of Prothya, has in-depth knowledge of the plasma industry and is a management personality with an impressive professional resume. With his great qualifications, he will continue the path successfully taken by Dr Floß", emphasises Rolf Hoffmann, Chairman of the Supervisory Board of Biotest AG.
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
|Phone:||0 61 03 - 8 01-0|
|Fax:||0 61 03 - 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1340373|
|End of News||DGAP News Service|